Radar · Neurology in San Francisco
Best Neurology Companies in San Francisco, United States
The 82 best Neurology companies in San Francisco, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Denali Therapeutics.
By Riya SenguptaFinancials
82companies tracked
$4Bdisclosed funding
0unicorns
53have raised
FLIAR INTELLIGENCE · NEUROLOGY × SAN FRANCISCO
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
74%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
223kcombined LinkedIn audience
50%of audience held by top 3
4companies hiring publicly (12 mo)
Ranked: Best Neurology companies in San Francisco
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Denali Therapeutics Developer of therapies to treat neurodegenerative diseases | $347M | 27 mo ago | 377 377 → 582 (+54%) | 2015 | Alexander Schuth Co-Founder | WordPressApple iCloud MailTypeScript+24 | 1,002 patents Neurodegenerative antibody therapies and enzyme‑fusion biologics for lysosomal disease treatment | — |
| 2 | Neurona Therapeutics Developer of cell-based therapies to treat intractable neurological diseases 55Funding top 22%Moat top 31%Growth top 32%AI top 45% All 8 signals ▾Fundingtop 22% Moattop 31% Growthtop 32% AItop 45% Talentbottom 49% Marketbottom 43% Globalbottom 39% Techbottom 30% Funding: Raised $316M across 9 rounds · 9 rounds over 18 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 55/100 | $316M | 14 mo ago | 67 67 → 116 (+73%) | 2008 | Cory Nicholas CEO | Apple iCloud MailApache HTTP ServerMicrosoft Advertising+5 | — | 1 award |
| 3 | Merge Labs Developer of brain-computer interfaces to maximize human ability, agency, experience 48Talent top 28%Funding top 31%AI top 45%Patents top 49% All 8 signals ▾Talenttop 28% Fundingtop 31% AItop 45% Patentstop 49% Innovationbottom 49% Techbottom 45% Globalbottom 42% Marketbottom 31% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $250M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $250M | 5 mo ago | — | 2025 | Sumner Norman Co-Founder | Apple iCloud MailGoogle WorkspaceNode.js+9 | 40 patents Real-time multi-user AR streaming and collaborative 3D object interaction | — |
| 4 | Alector Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders | $215M | 94 mo ago | 211 211 → 140 (-34%) | 2013 | — | DrupalApple iCloud MailMicrosoft 365+26 | 611 patents Therapeutic antibodies targeting neurodegeneration and immune modulation proteins. | — |
| 5 | Unity Biotechnology Developer of therapeutics solutions for numerous diseases of aging | $206M | 70 mo ago | 32 | 2009 | Jan Van Deursen Cofounder | DrupalPHPAmazon Web Services+20 | 244 patents Senolytic drugs and Tie‑2/VEGF antibodies for treating ocular vascular diseases | — |
| 6 | Tenvie Developer of small molecule therapies for neurological, cardiometabolic, and ophthalmic diseases | $200M | 17 mo ago | — | 2012 | Brian Cuneo Co-Founder & CLO | — | — | 4 job openings |
| 7 | ESCAPE Bio Developer of therapeutic solutions for treating genetic neurodegenerative diseases | $167M | 69 mo ago | 39 | 2015 | Julie Smith CEO | — | — | — |
| 8 | Alto Neuroscience AI-driven drug discovery platform for neurological diseases based on patients biomarkers 72Funding top 12%Patents top 25%Growth top 30%Moat top 32% All 11 signals ▾Fundingtop 12% Patentstop 25% Growthtop 30% Moattop 32% Innovationtop 33% Techtop 45% AItop 45% Globalbottom 49% Talentbottom 49% Newsbottom 44% Marketbottom 40% Funding: Raised $145M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Patents: 57 patents matched (strict assignee match) · 57 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 72/100 | $145M | 3 mo ago | 34 | 2019 | Amit Etkin Founder & CEO | BugHerdApple iCloud MailGoogle Workspace+15 | 57 patents Biomarker-guided neuropsychiatric therapeutics targeting depression and anhedonia | 1 award |
| 9 | Nura Bio Provider of solution for diagnosis of a neurological disorder and neuroprotective medicines | $141M | 21 mo ago | 25 | 2018 | Marc Freeman Co-Founder | — | — | — |
| 10 | Verge Genomics Developer of artificial intelligence powered platform for drug discovery and development | $134M | 54 mo ago | 46 46 → 27 (-41%) | 2015 | Peyton Huang Non-Executive Director and Co-Founder | — | — | 1 launch · 1 partnership |
| 11 | Blackthorn Therapeutics Developer of therapeutics for neurodevelopmental disorders | $130M | 84 mo ago | 38 | 2014 | — | — | — | — |
| 12 | Cortexyme Developer of therapeutics to treat neurodegenerative diseases | $108M | 76 mo ago | 21 | 2012 | Casey Lynch Co-Founder & CEO | — | 82 patents Gingipain enzyme inhibitors for treating periodontal and neurodegenerative diseases | — |
| 13 | Ambagon Developer of small-molecule therapeutics for the treatment of cancer | $103M | 16 mo ago | 49 | 2020 | Luc Brunsveld Co-Founder | WordPressMySQLPHP+20 | — | — |
| 14 | Cleave Therapeutics Developer of VCP/p97 inhibitors for oncology and neurodegenerative diseases | $103M | 82 mo ago | 18 | 2010 | Raymond Deshaies Co-Founder | — | — | — |
| 15 | Nudge Developer of whole-brain interfaces intended to improve human-brain interaction | $100M | 11 mo ago | — | 2024 | Quintin Frerichs Co-Founder | Apple iCloud MailGoogle WorkspaceRadix UI+8 | 12 patents Patents concentrated in health & consumer products | — |
| 16 | Openwater Provider of imaging technologies for medical diagnosis and treatments | $100M | 22 mo ago | — | 2016 | Mary Lou Jepsen Founder & CEO | Wix eCommerceCart FunctionalityWix+17 | — | — |
| 17 | AGY Therapeutics Small molecule and antibody drugs for neurology and oncology | $99M | 266 mo ago | — | 1998 | — | — | — | — |
| 18 | Blade Therapeutics Antifibrotic treatment strategies that address a wide variety of congenital and acquired diseases of fibrosis. | $93M | 80 mo ago | 30 | 2015 | — | — | — | — |
| 19 | CoMentis Pharma company focused on research and development for Neurovascular disease | $86M | 123 mo ago | 33 | 2004 | Scott Harkonen President and CEO | — | 89 patents Synthesis of chromane heterocycles and quinuclidine α7‑nicotinic modulators for neuro‑drugs | — |
| 20 | Concentric Analgesic Developer of platform for developing pro-drugs | $85M | 85 mo ago | 24 | 2014 | John Donovan Co-Founder & President | — | — | — |
| 21 | Perceive Bio Developer of therapeutics to treat diabetes and eye diseases | $78M | 41 mo ago | 12 | 2021 | Anne Rubin President | — | — | — |
| 22 | Switch Therapeutics Developer of therapeutics for neurological disorders | $72M | 39 mo ago | 25 | 2020 | Dee Datta Co-Founder & CEO | — | — | — |
| 23 | Therini Bio Limited information available | $62M | 13 mo ago | 13 13 → 15 (+15%) | 2016 | Daniel Burgess CEO | — | — | — |
| 24 | CODA Biotherapeutics Developer of gene therapy-based analgesics for the treatment of neuropathic pain disorder | $62M | 54 mo ago | 22 | 2014 | Mitchell H Finer Co-Founder | — | 32 patents Therapeutic peptide/protein compositions targeting neurological disorders. | — |
| 25 | XWPharma Developer of drugs for treating neurological disorders like epilepsy, Parkinson's & others | $58M | 69 mo ago | 15 | 2014 | Leonard Blum President & CEO | — | 22 patents Formulating gamma‑hydroxybutyric acid derivatives and excipient granulation for drug delivery | — |
| 26 | Noctrix Health Developer of wearable therapeutic device to treat neurological disorders | $57M | 9 mo ago | 8 | 2016 | — | WordPressApple iCloud MailMySQL+16 | — | — |
| 27 | ReviR Therapeutics Developer of RNA-based therapeutics for multiple diseases 35Funding top 26%AI top 45%Moat top 47%Talent bottom 49% All 8 signals ▾Fundingtop 26% AItop 45% Moattop 47% Talentbottom 49% Marketbottom 36% Globalbottom 36% Techbottom 31% Newsbottom 18% Funding: Raised $54.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) AI: Product described with: machine learning rank vs industry peers · Fliar Intelligence Index 35/100 | $54M | 2 mo ago | 29 | 2021 | Yang Li Co-Founder | UbuntuElement UIVue.js+6 | — | — |
| 28 | Mahzi Developer of therapeutics for rare genetic neurodevelopmental disorders | $53M | 56 mo ago | 7 | 2018 | Yael Weiss CEO | WordPressMySQLPHP+18 | — | — |
| 29 | Titan Pharma A specialty pharmaceutical company developing proprietary therapeutics for select chronic diseases | $38M | 11 mo ago | 11 | 1992 | — | Apple iCloud MailMicrosoft 365Apache HTTP Server+8 | — | — |
| 30 | Adynxx Developer of oligonucleotide technology for developing chronic pain management drugs | $36M | 80 mo ago | 7 | 2007 | — | — | 66 patents Nucleic‑acid‑based therapeutics and delivery systems for pain relief via gene expression modulation | — |
| 31 | Neuro42 AI Provider of MRI and robotics technology for neurology | $30M | 9 mo ago | 34 | 2020 | Abhita Vohra Co-Founder & CSO | WebflowSwiperjQuery+8 | 42 patents Low-field MRI hardware integration, AI‑enhanced image reconstruction, and electromagnetic interference mitigation. | — |
| 32 | OncoSynergy Developer of resistance mechanism inhibitors to treat cancer 11Funding top 28%Moat top 32%Patents bottom 48%Global bottom 42% All 6 signals ▾Fundingtop 28% Moattop 32% Patentsbottom 48% Globalbottom 42% Innovationbottom 33% Marketbottom 18% Funding: Raised $26.7M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Moat: Editorial + unicorn rating 5/10 · IP moat: 26 patents rank vs industry peers · Fliar Intelligence Index 11/100 | $27M | 1 mo ago | 3 | 2011 | — | — | 26 patents Therapeutic anti‑integrin β1 antibodies for oncology applications | — |
| 33 | Reset Therapeutics Developer of psychedelic therapeutics for mental illness | $25M | 96 mo ago | 26 | 2008 | — | — | — | — |
| 34 | Herophilus Developer of drug discovery platform to treat neurological disorders | $25M | 93 mo ago | 28 | 2017 | Sean Escola Co-Founder and Chief Neuroscientist | — | 8 patents Neuroimmune organoid platforms and epigenetic MECP2 modulation for neuroinflammatory therapies | — |
| 35 | SiteOne Therapeutics Sodium ion channel 1.7 (Na 1.7) inhibitors for acute and chronic pain. | $24M | 13 mo ago | — | 2010 | John Mulcahy Co-Founder & CEO | — | — | — |
| 36 | SOLEY Therapeutics Developer of stem cell secreted factors for the treatment of myocardial infarction and stroke | $20M | 5 mo ago | 10 | 2018 | Yerem Yeghiazarians Co-Founder & CEO | — | — | 1 job opening |
| 37 | iZumi Bio Development of stem cell lines and stem cell therapeutics. | $20M | 206 mo ago | 61 | 2007 | John Walker CEO | — | — | — |
| 38 | Lighthouse Pharma Developer of therapeutics for neurology and infectious diseases 11Funding top 46%Talent bottom 49%Tech bottom 45%Global bottom 25% All 5 signals ▾Fundingtop 46% Talentbottom 49% Techbottom 45% Globalbottom 25% Marketbottom 18% Funding: Raised $15.2M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 11/100 | $15M | 2 mo ago | 4 | 2019 | Casey Lynch Chief Executive Officer | WixSentryBootstrap+10 | — | — |
| 39 | Epiodyne Developing opioid medicines for pain management and opioid use disorder | $14M | 50 mo ago | 4 | 2016 | Douglas Crawford CEO | — | 25 patents Design and synthesis of novel opioid receptor ligands for pain and addiction therapeutics. | — |
| 40 | Xalud Therapeutics Gene therapy company restoring immune balance to treat chronic inflammation | $12M | 74 mo ago | 19 | 2009 | — | — | — | — |
| 41 | Darmiyan Platform for presymptomatic diagnosis of neurodegenerative disorders | $10M | 32 mo ago | 16 | 2015 | — | WordPressMySQLPHP+18 | 7 patents AI-driven neuroimaging analysis for brain disorder diagnosis | — |
| 42 | Eumentis Therapeutics Developer of therapeutics for neuropsychiatric conditions | $10M | 39 mo ago | 5 | 2019 | Mark Tepper President & CEO | — | — | — |
| 43 | Montara Therapeutics Developer of therapeutics for neurological diseases | $8M | 15 mo ago | — | 2023 | Kevan Shokat Co-Founder | — | — | 1 launch · 1 award |
| 44 | GABAeron Developer of stem cell-based therapies to treat neurodegenerative diseases | $8M | 18 mo ago | — | 2017 | Sheng Ding Co-Founder | — | — | — |
| 45 | Nine Square Therapeutics Developer of small molecule therapeutics for treating people with movement disorders | $4M | 33 mo ago | 9 | 2020 | Matthew Jacobson Co-Founder & Director | — | — | — |
| 46 | Elysium Therapeutics Developing innovative solutions to combat opioid overdose and reduce opioid abuse | $2M | 4 mo ago | 2 | 2013 | Alex Sturmer President | — | — | — |
| 47 | MicroQuin Developer of therapies for treating multiple diseases | $2M | 13 mo ago | 4 | 2016 | Scott Robinson Founder | — | 13 patents Peptide-based anticancer therapeutics and substituted chalcone small‑molecule drugs | — |
| 48 | Humanity Neurotech Developer of medical devices for the treatment of brain disorders | $1M | 25 mo ago | — | 2019 | Blake Gurfein Founder & CEO | — | 3 patents Low‑field magnetic neurostimulation devices for therapeutic pulse‑burst treatments | — |
| 49 | Exin Therapeutics Developer of precision genetic therapies targeting dysregulated neural circuits across various disorders | $500K | 12 mo ago | — | 2024 | Gabriel Santero Co-Founder and CEO | — | — | — |
| 50 | Uncommon Therapeutics Developer of therapeutics for rare, uncommon diseases | $500K | 15 mo ago | — | 2024 | Noah Auerhahn Co-Founder & CEO | — | — | — |
Top 12 Neurology companies in San Francisco
#1
Public · San Francisco, California · founded 2019 · 34 employees$144.7Mraised▾
Public · San Francisco, California · founded 2019 · 34 employees
AI-driven drug discovery platform for neurological diseases based on patients biomarkers. The company's platform measures patients biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to develop personalized psychiatric drugs. The company has pipeline of drugs including ALTO-100 for depression, ALTO-101 for neurodegenerative diseases, and more.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 12%Patents
top 25%Growth
top 30%Moat
top 32%Innovation
top 33%Tech
top 45%Funding: Raised $145M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) · Last round Post IPO (Mar 2026)
Patents: 57 patents matched (strict assignee match) · 57 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Growth: Headcount 12 → 34 (+183%) across vintages · Fresh capital in last 24 mo
Audience (LinkedIn): 25k LinkedIn followers — 11.0% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Mar 2026Post IPO$120M
- Oct 2025Post IPO$50M
- Nov 2023Series C$45M
- Jan 2023Venture Debt—
Founders & team
Investors
Lightswitch Capital, Novartis, Sobrato, Alkeon Capital Management, Windham Venture Partners, What If Ventures
Tech stack
Apple Icloud MailAstraBugherdCloudflareCore-JsElementor
#2
Seed · San Francisco, California · founded 2025$250Mraised▾
Seed · San Francisco, California · founded 2025
Developer of brain-computer interfaces to maximize human ability, agency, experience. It focuses on creating new approaches to interact with the brain. The aim is to develop high-bandwidth brain-computer interfaces. These interfaces integrate with advanced artificial intelligence. The goal is to make the technology safe and accessible. The company seeks to restore lost abilities and support healthier brain states. It also aims to deepen connections and expand creative potential.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Talent
top 28%Funding
top 31%AI
top 45%Patents
top 49%Innovation
bottom 49%Tech
bottom 45%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $250M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Jan 2026)
AI: Product described with: artificial intelligence
Audience (LinkedIn): 6k LinkedIn followers — 2.7% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Jan 2026Seed$250M
Founders & team
Investors
OpenAI
Tech stack
Apple Icloud MailGodaddyGoogle WorkspaceHstsNext.JsNext.Js App Router
#3
Series A · San Francisco, California · founded 2021 · 29 employees$54Mraised▾
Series A · San Francisco, California · founded 2021 · 29 employees
Developer of RNA-based therapeutics for multiple diseases. The company is leveraging machine learning technology and innovative RNA techniques to develop medicines for the treatment of cancer, rare genetic disorders, and infectious diseases.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 26%AI
top 45%Moat
top 47%Talent
bottom 49%Market
bottom 36%Global
bottom 36%Funding: Raised $54.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) · Last round Series A (Apr 2026)
AI: Product described with: machine learning
Moat: Editorial + unicorn rating 3/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. CureCMT) announced in 12 mo
Funding rounds
- Apr 2026Series A—
- Nov 2025Grant (prize money)$4.6M
- Jul 2024Series A$30M
- Jan 2022Seed$20M
Founders & team
Investors
Lapam Capital, CDH, 5Y Capital, Yael Capital, Cmtrf, XtalPi
Tech stack
Core-JsElement UiGoogle WorkspaceLodashNginxSwiper
#4
Acquired · San Francisco, California · founded 2011 · 3 employees$26.7Mraised▾
Acquired · San Francisco, California · founded 2011 · 3 employees
Developer of resistance mechanism inhibitors to treat cancer. It targets multiple hallmarks of cancer progression and have demonstrated efficacy as monotherapy and in strategic combinations. The lead drug program OS2966 therapeutic antibody blocking a cell surface receptor for the treatment of glioblastoma, ovarian, pancreatic cancer, and malignant meningioma.
Fliar Intelligence Index™ 11how this company ranks against its industry peers
Funding
top 28%Moat
top 32%Patents
bottom 48%Global
bottom 42%Innovation
bottom 33%Market
bottom 18%Funding: Raised $26.7M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) · Last round Series A (May 2026)
Moat: Editorial + unicorn rating 5/10 · IP moat: 26 patents
Patents: 26 patents matched (strict assignee match) · 4 filings since 2022 vs 12 in 2017-21 · Latest publication 2023
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- May 2022Series A$3.5M
- Nov 2020Conventional Debt$250K
- Sep 2020Series A$3.2M
- Jan 2020Grant (prize money)$300K
Investors
National Cancer Institute, Connecticut Innovations, Navation, KICC, HHS, JLABS
#5
Acquired · San Francisco, California · founded 2008 · 67 employees$315.7Mraised▾
Acquired · San Francisco, California · founded 2008 · 67 employees
Developer of cell-based therapies to treat intractable neurological diseases. It generate therapeutic compositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. It offers NRTX-1001, an inhibitory neuron therapy for epilepsy by GABAergic inhibition, reduce seizure activity, and repair the affected neural network.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 22%Moat
top 31%Growth
top 32%AI
top 45%Talent
bottom 49%Market
bottom 43%Funding: Raised $316M across 9 rounds · 9 rounds over 18 yrs (0.5/yr) · Last round Series E (Mar 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Growth: Headcount 55 → 67 (+22%) across vintages · Fresh capital in last 24 mo
Audience (LinkedIn): 12k LinkedIn followers — 5.3% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Clinical Specialist
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Mar 2025Series E$102M
- Feb 2024Series E$120M
- Dec 2022Series D$72M
- Jun 2021Series C$41.5M
Founders & team
Investors
UCB Ventures, Ironfire Ventures, Alexandria, Sphera Fund, The Column Group, Viking Global Investors
Tech stack
Apache Http ServerApple Icloud MailCookieyesGoogle AnalyticsGoogle Hosted LibrariesHsts
#6
Series A · San Francisco, California · founded 2019 · 4 employees$15.2Mraised▾
Series A · San Francisco, California · founded 2019 · 4 employees
Developer of therapeutics for neurology and infectious diseases. It offers a pipeline of drug candidates which include LHP588, is a next-generation gingipain inhibitor for gingivalis infection which causes Alzheimer's disease, Parkinson's disease, and oral dyslapsia. It also offers LHP852 for gingivalis infection and LHP803 for coronavirus infection.
Fliar Intelligence Index™ 11how this company ranks against its industry peers
Funding
top 46%Talent
bottom 49%Tech
bottom 45%Global
bottom 25%Market
bottom 18%Funding: Raised $15.2M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series A (Apr 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Tech: 13 technologies across 4/8 capability areas · Cloud: Google Cloud, Google Cloud Cdn · Observability: Sentry
Audience (LinkedIn): 705 LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: CTA/Sr. CTA
Activity (LinkedIn): 1 partnerships · 1 expansions (incl. Lighthouse Pharmaceuticals, Inc.) announced in 12 mo
Funding rounds
- Apr 2026Series A$15.2M
Founders & team
Investors
Double Point Ventures
Tech stack
BootstrapGoogle CloudGoogle Cloud CdnGsapHstsHttp/3
#7
Series C · San Francisco, California · founded 2016 · 8 employees$57Mraised▾
Series C · San Francisco, California · founded 2016 · 8 employees
Noctrix Health is engaged in developing prescription-grade wearable therapeutic devices. They are developing a medical device for treating chronic neurological disorders, especially to treat the symptoms of restless leg syndrome.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 22k LinkedIn followers — 10.0% of this cohort's audience
Funding rounds
- Aug 2025Conventional Debt—
- Aug 2025Series C$33.5M
- May 2025Grant (prize money)$2.2M
- Jan 2024Series C$40M
Investors
Treo Ventures, Orbimed, LivaNova, Sectoral, Angelini Ventures, ResMed
Tech stack
Apple Icloud MailBeaver BuilderCdnjsCloudflareCore-JsElementor
#8
Series A · San Francisco, California · founded 2024$100Mraised▾
Series A · San Francisco, California · founded 2024
Developer of whole-brain interfaces intended to improve human-brain interaction. It offers a phased-array ultrasound-based wearable device capable of both imaging and modulating brain activity aiming to enable at-home devices for mood, memory, focus, or treating chronic conditions like pain, addiction, and anxiety.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 8k LinkedIn followers — 3.8% of this cohort's audience
Funding rounds
- Jul 2025Series A$100M
Founders & team
Investors
Thrive Capital, Greenoaks
Tech stack
Apple Icloud MailAstroAzureCloudflareCloudflare Browser InsightsGoogle Workspace
#9
Series C · San Francisco, California · founded 2018 · 10 employees$20Mraised▾
Series C · San Francisco, California · founded 2018 · 10 employees
Soley Therapeutics is developing stem cell-secreted factors for the treatment of ischemia-related diseases including myocardial infarction and stroke. These drugs will be administered to patients at the time of heart attack and stroke to minimize the damage in the heart and brain respectively. The company's lead product increases cardiomyocyte (heart muscle) viability, decreases infarct scar size, and improves cardiac function in the acute setting of a heart attack.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers
Hiring: 1 hiring post in 12 mo (public) · hiring: Senior Machine Learning Engineer
Activity: 1 product launches announced in 12 mo
Funding rounds
- Jan 2026Series C$200M
- Dec 2020Series B$20M
Founders & team
Investors
Surveyor Capital, HRTG Partners, RWN Management, Breyer Capital, GordonMD Global Investments, Dougleonefamilyfund
#10
Series A · San Francisco, California · founded 2020 · 34 employees$30Mraised▾
Series A · San Francisco, California · founded 2020 · 34 employees
Provider of MRI and robotics technology for neurology. The company is developing an intraoperative MR, AI, and a robot that allows easy access to MR imaging for screening, diagnosis, and interventions of neurological diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 7k LinkedIn followers — 3.0% of this cohort's audience
Funding rounds
- Sep 2025Grant (prize money)$1.9M
- Feb 2025Grant (prize money)$1.9M
- Aug 2024Series A$15.6M
- May 2024Series A$6.7M
Founders & team
Investors
Zynext Ventures, Zepp Labs, ShangBay Capital, HHS, Kyto Technology & Life Science, Blacktop Capital
Tech stack
CloudflareGoogle Font ApiGoogle Hosted LibrariesHstsHttp/3Jquery
#11
Series A · San Francisco, California · founded 2016 · 13 employees$62.4Mraised▾
Series A · San Francisco, California · founded 2016 · 13 employees
Limited information available
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Funding rounds
- May 2025Series A$39M
- Jan 2025Grant (prize money)$3M
- Mar 2023Conventional Debt—
- Mar 2023Series A$36M
Founders & team
Investors
Dolby Family Ventures, Alzheimer's Drug Discovery, SV Health Investors, MRLV, Sanofi Ventures, Lilly
#12
Public · San Francisco, California · founded 1992 · 11 employees$37.9Mraised▾
Public · San Francisco, California · founded 1992 · 11 employees
Titan develops proprietary therapeutics for the treatment of select chronic diseases  utilizing its long-term, continuous drug delivery platform, ProNeura. The company's lead product candidate is Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction.  A New Drug Application for Probuphine was accepted by the U.S. Food and Drug Administration in September 2015 and the FDA has assigned an action date of May 27, 2016. If approved, Probuphine would be the first marketed product to provide maintenance treatment of opioid addiction continuously for six months following a single administration procedure. Other candidates include ropinirole and T3 implants in the preclinical stage for Parkinson's disease and hypothyroidism respectively
Funding rounds
- Jun 2025Post IPO$600K
- Feb 2022Post IPO$1.5M
- Oct 2021Grant (prize money)—
- Jan 2021Post IPO$9.7M
Investors
Gates, Horizon, NIDA, HHS, Blue Harbour Asset Management, Apple Tree Partners
Tech stack
Apache Http ServerApple Icloud MailFancyboxGodaddyGoogle AnalyticsGoogle Font Api
Funding & investor landscape
$4Btotal disclosed funding
58companies funded
181disclosed rounds
2rounds last 90 days
Most active investors
Y Combinator4 rounds
Notable founders
Amit Etkin
Founder & CEO · Alto Neuroscience
Sumner Norman
Co-Founder · Merge Labs
Sandro Herbig
Co-Founder · Merge Labs
Yang Li
Co-Founder · ReviR Therapeutics
Cory Nicholas
CEO · Neurona Therapeutics
Casey Lynch
Chief Executive Officer · Lighthouse Pharma
Quintin Frerichs
Co-Founder · Nudge
Fred Ehrsam
Co-Founder & CEO · Nudge
Yerem Yeghiazarians
Co-Founder & CEO · SOLEY Therapeutics
Kurosh Ameri
Co-Founder · SOLEY Therapeutics
Abhita Vohra
Co-Founder & CSO · Neuro42 AI
Amit Vohra
Co-Founder & CEO · Neuro42 AI
Prism market signals · United States · country-scoped Prism corpus, 672,586 docs
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding falling · growth flat
RESEARCH SIGNALS · United States
How research on Neuroscience & Neurotech is moving in the United States
A read on the academic research around Neuroscience & Neurotech — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 8,477 United States-affiliated papers.
research sentiment over time
200820172026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 28% → 43% across 2008–2026.
top research entities
- Neurological Surgery622
- Harvard University448
- University of Florida313
- University of California, San Francisco267
- Emory University266
leading researchers
Michael S. Okun · Kelly D. Foote · Philip A. Starr · Cameron C. McIntyre · Jill L. Ostrem · Joshua K. Wong · Andrés M. Lozano · Sameer A. Sheth
▲
Breakthroughs1,435 · 17%
▲ 14%→19% share
▲1.4× share momentum5 median citations51% since 2021mostly methods-led
Breakthroughs are rising (14%→19% of field), led by Deep brain stimulation.
rising sub-themes (early→recent)
- Deep brain stimulation180→297
- Neuromodulation38→144
- Stimulation97→176
- Brain stimulation19→78
- Neurostimulation54→105
Newly emergingBrain mapping 0→8 · Biomarker 0→7 · Convolutional neural network 0→7
Landmark Phenomenology and classification of dystonia: A consensus update · 2,210 cites
◆
Advancements4,187 · 49%
▲ 48%→51% share
▲1.1× share momentum8 median citations47% since 2021mostly empirical
Advancements are rising (48%→51% of field), led by Deep brain stimulation.
rising sub-themes (early→recent)
- Deep brain stimulation859→1079
- Neuromodulation95→285
- Neurostimulation157→315
- Stimulation383→535
- Epilepsy60→211
Newly emergingDorsal root ganglion 0→9 · Cochrane Library 0→7 · Entrainment (biomusicology) 0→7
Landmark Neural Stimulation and Recording Electrodes · 2,184 cites
▼
Concerns1,680 · 20%
▼ 22%→18% share
▼0.8× share momentum10 median citations42% since 2021mostly empirical
Concerns are cooling (22%→18% of field), led by Neurostimulation.
rising sub-themes (early→recent)
- Neurostimulation45→123
- Neuromodulation41→110
- Epilepsy21→60
- Transcranial magnetic stimulation17→38
- Chronic pain3→23
Newly emergingArtifact (error) 0→10 · Spinal cord stimulator 0→9 · Meta-analysis 0→8
Landmark A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease · 807 cites
RESEARCH HOTSPOTS · United States
Where neurotech is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston722 · +0.44
SF Bay Area572 · +0.43
New York501 · +0.38
Atlanta304 · +0.34
Pittsburgh282 · +0.50
Chicago268 · +0.35
Seattle262 · +0.48
Los Angeles260 · +0.42
Philadelphia220 · +0.42
Ann Arbor134 · +0.40
PATENT SIGNAL · United States
Who's filing neurotech patents in the United States
United States neurotech patent filing is accelerating — 2,059 filings from 781 assignees (2016–2025), led by Boston Scient Neuromodulation, Medtronic, Advanced Neuromodulation Systems; annual filings 205→349.
2,059 filings781 assigneespeak 349/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Boston Scient Neuromodulation865
- Medtronic277
- Advanced Neuromodulation Systems124
- Cardiac Pacemakers75
- Pacesetter67
- Cyberonics54
- Axonics43
- PREC Neuroscience43
Common questions
How many Neurology companies are there in San Francisco, United States?
Radar tracks 82 indexable Neurology companies headquartered in San Francisco, United States that meet our profile-completeness bar.
What is the total funding raised by Neurology companies in San Francisco, United States?
The Neurology companies in San Francisco, United States on this list have raised a combined $4B in disclosed equity funding across 58 funded companies.
Which is the highest-funded Neurology company in San Francisco, United States?
Denali Therapeutics is the highest-funded Neurology company in San Francisco, United States, with $347M in disclosed equity funding.
How many Neurology companies in San Francisco, United States are funded?
58 of the 82 Neurology companies in San Francisco, United States on this list have disclosed at least one equity funding round.
How many Neurology unicorns are there in San Francisco, United States?
None of the Neurology companies in San Francisco, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in San Francisco, United States Neurology companies?
The most active investors in San Francisco, United States Neurology companies on this list include HHS, Dolby Family Ventures, Orbimed, Arch Venture Partners, JLABS.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.